GT Biopharma, Inc. - FORM 10-Q - EX-32.2 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - May 15, 2020

Attached files

file filename
EX-10.5 - FORM OF REGISTRATION RIGHTS AGREEMENT BY AND AMONG THE COMPANY AND THE BUYERS, D - GT Biopharma, Inc.gtbp_ex105.htm
EX-32.1 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - GT Biopharma, Inc.gtbp_ex321.htm
EX-31.2 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - GT Biopharma, Inc.gtbp_ex312.htm
EX-31.1 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - GT Biopharma, Inc.gtbp_ex311.htm
EX-10.7 - CLINICAL TRIAL AGREEMENT WITH UNIVERSITY OF MINNESOTA - GT Biopharma, Inc.gtbp_ex107.htm
EX-10.6 - FORM OF NOTE, DATED APRIL/MAY, 2020. - GT Biopharma, Inc.gtbp_ex106.htm
EX-10.4 - SECURITIES PURCHASE AGREEMENT BY AND AMONG THE COMPANY AND THE BUYERS, DATED APR - GT Biopharma, Inc.gtbp_ex104.htm
EX-10.3 - FORM OF NOTE, DATED JANUARY 30, 2020. - GT Biopharma, Inc.gtbp_ex103.htm
EX-10.2 - FORM OF REGISTRATION RIGHTS AGREEMENT BY AND AMONG THE COMPANY AND THE BUYERS, D - GT Biopharma, Inc.gtbp_ex102.htm
EX-10.1 - SECURITIES PURCHASE AGREEMENT BY AND AMONG THE COMPANY AND THE BUYERS, DATED JAN - GT Biopharma, Inc.gtbp_ex101.htm
10-Q - QUARTERLY REPORT - GT Biopharma, Inc.gtbp_10q.htm
 
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report on Form 10-Q of GT Biopharma, Inc. (the “Company”), for the quarterly period ended March 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Steven Weldon, Chief Financial Officer of the Company, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, do hereby certify, to my knowledge that:
 
(1)           The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 15 U.S.C. 78m(a) or 780(d)); and
 
(2)           The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
 
 
 
Date: May 15, 2020
 
/s/ Steven Weldon
 
 
 
Steven Weldon
 
 
 
CFO, Chief Accounting Officer, and Director
 
 
 
 
 
 
A signed original of this written statement required by Section 906 has been provided to GT Biopharma, Inc. and will be retained by GT Biopharma, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
 
 

Stock widget

Investing forum

GT Biopharma, Inc. Reports